282 completed, 113 terminated, 81 recruiting, 59 active not recruiting. 609 Phase 1, 214 Phase 2.
Follow Carcinoma, Renal Cell: new trials by email Literature Review of Carcinoma, Renal Cell trials Research Report on Carcinoma, Renal Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2027-01-01 | 2026-10-28 |
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 112 | 2026-12-31 | 2026-09-30 |
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma casdatifan - Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 12 | 2026-09-21 | 2026-09-25 |
| Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma Personalized Neoantigen Polyepitope Peptide Vaccine - Renal Cell Carcinoma, Advanced | Phase 1 | Not yet recruiting | Jian Lin | 8 | 2026-09-01 | 2026-07-07 |
| Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM 68Ga-NYM096 injection - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Norroy Bioscience Co., LTD | 20 | 2026-09-01 | 2026-08-17 |
| GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours Fludarabine, Cyclophosphamide, GCAR1 - Alveolar Soft Part Sarcoma, Renal Cell Carcinoma | Phase 1 | Recruiting | Canadian Cancer Trials Group | 30 | 2026-08-30 | 2026-10-16 |
| Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01) Cyclophosphamid, Fludarabine, Interleukin 2 subcutaneous injection - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | Hangzhou Huasai Biomedicine Co., Ltd. | 15 | 2026-08-23 | 2026-10-14 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 - Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 265 | 2026-07-20 | 2026-09-28 |
| A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors VMD-102 - Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | VM Discovery, Inc. | 111 | 2026-07-16 | 2026-08-19 |
| A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma PD-32766D (a Copper-64 [64Cu] labeled peptide), PD-32766T (an Actinium-225 [225Ac] labeled peptide) - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | PeptiDream Inc. | 60 | 2026-07-07 | 2026-09-18 |
| Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma Cyclophosphamide, Fludarabine, LNK001 - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-07-02 | 2026-10-09 |
| To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer Anti-Human CD70 T-Cell Injection - Renal Cell Carcinoma (RCC) | Phase 1 | Recruiting | Hrain Biotechnology Co., Ltd. | 18 | 2026-06-30 | 2026-07-02 |
| A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors HH160 - Solid Tumor, Non-small Cell Lung Cancer | Phase 1 | Recruiting | Huahui Health | 299 | 2026-06-11 | 2026-08-21 |
| A Phase 1 Study of the Safety and Tolerability of CTX-10726 CTX-10726 - Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC) | Phase 1 | Recruiting | Compass Therapeutics | 70 | 2026-05-28 | 2026-10-23 |
| UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma UCL70805F - CD70-positive Advanced Renal Clear Cell Carcinoma | Phase 1 | Not yet recruiting | UTC Therapeutics Inc. | 21 | 2026-05-01 | 2026-03-30 |
| Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors EXS74539 - Solid Tumor, Small Cell Lung Cancer (SCLC) | Phase 1 | Recruiting | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 40 | 2026-04-13 | 2026-06-10 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) Pumitamig, Ipilimumab, Cabozantinib - Advanced Renal Cell Carcinoma (RCC) | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 474 | 2026-03-26 | 2026-10-23 |
Showing 20 of 609. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (195) · Melanoma (180) · Kidney Neoplasms (127) · Colorectal Neoplasms (106) · Squamous Cell Carcinoma of Head and Neck (98) · Ovarian Neoplasms (85) · Stomach Neoplasms (79) · Neoplasm Metastasis (78) · Breast Neoplasms (77) · Carcinoma, Hepatocellular (75) · Neoplasms (74) · Triple Negative Breast Neoplasms (67) · Uterine Cervical Neoplasms (65) · Urinary Bladder Neoplasms (61)
Female Urogenital Diseases (609) · Female Urogenital Diseases and Pregnancy Complications (609) · Male Urogenital Diseases (609) · Urogenital Diseases (609) · Neoplasms by Site (608) · Neoplasms, Glandular and Epithelial (608) · Neoplasms by Histologic Type (605) · Urologic Diseases (605) · Urogenital Neoplasms (604) · Adenocarcinoma (603) · Urologic Neoplasms (602) · Kidney Diseases (601) · Carcinoma (599) · Neoplasms (535) · Kidney Neoplasms (482)
pembrolizumab (85) · Nivolumab (67) · Sunitinib (28) · Bevacizumab (26) · Ipilimumab (26) · Cyclophosphamide (25) · Everolimus (23) · cabozantinib (21) · fludarabine (17) · aldesleukin (15) · Axitinib (14) · Magnetic Resonance Spectroscopy (14) · Paclitaxel (14) · Sorafenib (14) · atezolizumab (14)
National Cancer Institute (NCI) (46) · Pfizer (16) · Novartis Pharmaceuticals (14) · M.D. Anderson Cancer Center (13) · Memorial Sloan Kettering Cancer Center (12) · Bristol-Myers Squibb (11) · Merck Sharp & Dohme LLC (11) · GlaxoSmithKline (10) · Celldex Therapeutics (8) · City of Hope Medical Center (8) · Jonsson Comprehensive Cancer Center (8) · Incyte Corporation (7) · Eli Lilly and Company (6) · Incyte Biosciences International Sàrl (6) · Ludwig Institute for Cancer Research (6)
United States (461) · Spain (56) · Australia (55) · Canada (51) · France (49) · China (48) · United Kingdom (40) · Italy (34) · South Korea (34) · Belgium (25) · Germany (25) · Japan (25) · Netherlands (23) · Israel (15) · Taiwan (14)
Sumanta K Pal (4) · Brenda Sandmaier (3) · John E. Janik, MD (3)
PMID 32499241, PMID 39462179, PMID 31401903, PMID 37093350, PMID 40712111, PMID 11410496, PMID 12727829, PMID 15814645, PMID 17395103, PMID 17893567, PMID 18245546, PMID 18272024, PMID 18470481, PMID 19179301, PMID 19755389, PMID 20068553, PMID 20142724, PMID 20145168, PMID 20179219, PMID 20305636, PMID 20797845, PMID 21277078, PMID 21403127, PMID 21447719, PMID 21917625, PMID 21994418, PMID 22045104, PMID 22129044, PMID 22159179, PMID 22259028, PMID 22430088, PMID 22461641, PMID 22658127, PMID 22980441, PMID 23377668, PMID 23514360, PMID 23586712, PMID 23726267, PMID 23747347, PMID 23756764, PMID 23861247, PMID 24089446, PMID 24124874, PMID 24308791, PMID 24456794, PMID 24464355, PMID 24474568, PMID 24504486, PMID 24590637, PMID 24618589
2023 (14), 2018 (7), 2019 (7), P30CA033572 (7), 2016 (5), 2025 (5), 2015 (4), P30CA015704 (4), U01CA070095 (4), U01CA132123 (4), 2014 (3), 2017 (3), P30CA072720 (3), U01CA062491 (3), UM1CA186644 (3)